Trials / Conditions / mCRPC (Metastatic Castration-resistant Prostate Cancer)

mCRPC (Metastatic Castration-resistant Prostate Cancer)

12 registered clinical trials studyying mCRPC (Metastatic Castration-resistant Prostate Cancer) — 11 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC NCT07451795	Fudan University	Phase 2
Recruiting	A Study of MHB048C in Patients With Advanced Solid Tumors NCT07192120	Minghui Pharmaceutical (Hangzhou) Ltd	Phase 1 / Phase 2
Recruiting	A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) NCT07103018	K36 Therapeutics, Inc.	Phase 1
Recruiting	Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity NCT07302763	Frederic Pouliot	N/A
Recruiting	A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Receive NCT06844383	Prostate Cancer Clinical Trials Consortium	Phase 2
Recruiting	Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer NCT06801236	Acerand Therapeutics (Hong Kong) Limited	Phase 1
Recruiting	Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 NCT06785636	Pathos AI, Inc.	Phase 1 / Phase 2
Not Yet Recruiting	Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC NCT06768255	Ding-Wei Ye	Phase 3
Recruiting	Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer NCT06190899	Celcuity Inc	Phase 1 / Phase 2
Recruiting	Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Pros NCT06702995	Evopoint Biosciences Inc.	Phase 1 / Phase 2
Recruiting	Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tu NCT05283330	Orano Med LLC	Phase 1
Terminated	A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma NCT03207867	Novartis Pharmaceuticals	Phase 2